Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for nanotechnology industry professionals · Tuesday, March 19, 2019 · 479,697,230 Articles · 3+ Million Readers

Global $1.81 Bn Antisense & RNAi Therapeutics Market 2017-2019 & 2025 - On-Going Developments in Biological Vectors and Nanotechnology has Fuelled Market Growth

/EIN News/ -- Dublin, March 07, 2019 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics Market Analysis Report By Application (Oncology, Cardiovascular, Infectious Diseases), By Technology (siRNA, miRNA), By Route of Administration, And Segment Forecasts, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.

The global antisense and RNAi therapeutics market size is expected to reach USD 1.81 billion by 2025, recording a 7.5% CAGR during the forecast period.

Rising instances of external funding to conduct clinical studies pertaining to introduction of novel drug moieties plays a vital role in the process of new product development. This, along with ongoing developments in biological vectors and nanotechnology, has fuelled market growth.

Multinational healthcare establishments promote awareness and aid in finding novel therapies for treatment of different disorders. Private institutes such as California Institute of Regenerative Medicine and ALS Association are involved in conducting trials by funding research institutes and pharmaceutical organizations and this is expected to significantly fuel sector growth. Moreover, government initiatives for speeding the development of drug delivery platforms in order to reduce disease burden are attributive for industrial growth.

Antisense and RNAi therapeutics services are applicable in treatment of a wide range of diseases that target nucleic acid and affect cell growth cycle. miRNA is attracting considerable interest in its ability to restore gene expression and correct protein production, thereby influencing industrial progress. Developments that involve the research of using different routes to deliver the desired effect of candidate moiety before its removal from blood are anticipated to fuel sector growth.

However, challenges associated with drug delivery are expected to impede growth to a certain extent. Delivery technologies that enable mitigation of off-target effects and undesirable immunological stimulation need to be introduced in order to reduce the effect of restraining factors.

Further key findings from the report suggest:

  • Antisense RNA technology accounted for the largest share in market revenue in 2017 owing to advantages associated with this technology over RNA interference
  • Based on the triggering of RNA molecules, this technology is segmented into siRNA and miRNA. Owing to significant involvement of miRNA in maintaining a cell's identity, these are used to provide deep insight to cancer metastasis
  • Usage of RNAi therapy to selectively target SNPs in genetic disorders is a major factor expected to provide this segment several potential treatment avenues over the forecast period
  • siRNA is highly specific and allows induction at advanced stages of cancer growth as compared to chemotherapy, which enables it to emerge as the dominant sub-segment in oncology applications
  • Extensive R&D programs carried out to develop an efficient method for the delivery of RNA silencing therapeutic products is anticipated to propel growth. These R&D programs are based on obtaining desired pharmacological action prior to removal of the product from the cytoplasm and systemic circulation
  • Isis Pharmaceuticals/ Ionis Pharmaceuticals, GSK, Alnylam Pharmaceuticals, Marina Biosciences, Sanofi-Genzyme, Quark Pharmaceuticals, Gene Signal, and Benitec Biopharma are major companies in the market involved in development and commercialization of products
  • Strong product portfolio in different phases of clinical trials and preclinical development programs is expected to contribute to the growth of this industry.

Key Topics Covered:

Chapter 1 Executive Summary
1.1 Market Snapshot

Chapter 2 Research Methodology
2.1 Information Procurement
2.2 List of Data Sources
2.3 Information or Data Analysis
2.4 Market Formulation & Validation

Chapter 3 Antisense & RNAi Therapeutics Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Presence of strong pipeline product portfolio
3.1.1.2 Introduction of technological advancements in drug delivery
3.1.1.3 Implementation of favorable government initiatives & external funding for R&D exercises
3.1.1.4 Rising collaborations between pharmaceutical companies
3.1.2 Market restraint analysis
3.1.2.1 Expensive and tedious research programs
3.1.2.2 Delivery of RNAi therapeutics and off-target effects
3.2 Antisense & RNAi Therapeutics - SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.3 Industry Analysis - Porter's
3.4 Penetration &Growth Prospect Mapping for Methods, 2017
3.5 Antisense & RNAi Therapeutics Ansoff Matrix, 2017
3.6 Antisense & RNAi therapeutics Pipeline Analysis
3.6.1 Olix Pharmaceuticals
3.6.2 Glaxo Smith Kline
3.6.3 Sanofi Aventis / Genzyme
3.6.4 Alnylam Pharmaceuticals
3.6.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals
3.6.6 Benitec Biopharma Ltd.
3.6.7 Arbutus Biopharma Ltd.
3.6.8 Silence Therapeutics
3.6.9 Bio-Path Holdings Inc.
3.6.10 Calando Pharmaceuticals
3.6.11 Gene Signal
3.6.12 iCo Therapeutics
3.6.13 Mirna Therapeutics/Synlogic
3.6.14 miRagen Therapeutics Inc.
3.6.15 Quark Pharmaceuticals
3.6.16 OncoGenex Pharmaceuticals Inc.
3.6.17 Rexahn Pharmaceuticals
3.6.18 Biomarin/Prosensa
3.6.19 Regulus Therapeutics
3.6.20 Rxi Pharmaceuticals
3.6.21 Sarepta Therapeutics
3.6.22 Sylentis S.A.
3.6.23 Silenseed
3.6.24 Dicerna Pharmaceuticals
3.6.25 Santaris
3.6.26 Sirnaomics Inc.

Chapter 4 Antisense & RNAi Therapeutics Market Categorization: Technology Estimates & Trend Analysis
4.1 Antisense & RNAi Therapeutics Market: Technology Movement Analysis
4.2 RNA interference
4.2.2 siRNA
4.2.3 miRNA
4.3 Antisense RNA

Chapter 5 Antisense & RNAi Therapeutics Market Categorization: Application Estimates & Trend Analysis
5.1 Global Antisense & RNAi Therapeutics Market: Application Movement Analysis
5.2 Antisense & RNAi therapeutics in oncology
5.3 Antisense & RNAi therapeutics market in cardiovascular diseases
5.4 Antisense & RNAi therapeutics market in respiratory disorders
5.5 Antisense & RNAi therapeutics market for renal diseases
5.6 Antisense & RNAi therapeutics market in neurodegenerative disorders
5.7 Antisense & RNAi therapeutics market in genetic disorders
5.8 Antisense & RNAi therapeutics market in infectious diseases
5.9 Antisense & RNAi therapeutics market in other diseases

Chapter 6 Antisense & RNAi Therapeutics Market Categorization: Route of Administration Estimates & Trend Analysis
6.1 Antisense & RNAi Therapeutics Market: Route of Administration Movement Analysis
6.2 Pulmonary delivery
6.3 Intravenous injections market
6.4 Intra-dermal injections
6.5 Intraperitoneal injections market
6.6 Topical delivery
6.7 Other delivery

Chapter 7 Antisense & RNAi Therapeutics Market Categorization: Regional Estimates & Trend Analysis, by Application, & Route of Administration
7.1 Antisense & RNAi Therapeutics Market Share By Region, 2017 & 2025

Chapter 8 Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/pbc3qx/global_1_81_bn?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Genomics
                    

22157.jpg

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release